EP1663205A1 - Use of 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity - Google Patents
Use of 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activityInfo
- Publication number
- EP1663205A1 EP1663205A1 EP04766644A EP04766644A EP1663205A1 EP 1663205 A1 EP1663205 A1 EP 1663205A1 EP 04766644 A EP04766644 A EP 04766644A EP 04766644 A EP04766644 A EP 04766644A EP 1663205 A1 EP1663205 A1 EP 1663205A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- treatment
- prophylaxis
- juvenile
- phenyl
- chlorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to a group of novel therapeutic and/or prophylactic uses of 4,5-dihydro-1 H-pyrazole derivatives and to pharmaceutical compositions containing one or more of these compounds as an active component for the novel uses.
- the 4,5-dihydro-1 H-pyrazoles are potent Cannabis-1 (CBi) receptor antagonists with outstanding utility for the novel medical uses provided by the present invention.
- Cannabinoids are present in the Indian hemp Cannabis Sativa L. and have been used as medicinal agents for centuries ( echoulam, R.; Feigenbaum, J.J. Prog. Med. Chem. 1987, 24, 159). However, only within the past ten years the research in the cannabinoid area has revealed pivotal information on cannabinoid receptors and their (endogenous) agonists and antagonists. The discovery and the subsequent cloning of two different subtypes of Cannabinoid receptors (CBi and CB 2 ) stimulated the search for novel cannabinoid receptor antagonists (Munro, S.; Thomas, K.L.; Abu-Shaar, M. Nature 1993, 365, 61.
- AM-630 lodopravadoline
- a representative example is lodopravadoline (AM-630), which was introduced in 1995.
- AM-630 is a CBi receptor antagonist, but sometimes behaves as a weak partial agonist (Hosohata, K.; Quock, R.M.; Hosohata, Y.; Burkey, T.H.; Makriyannis, A.; Consroe, P.; Roeske, W.R.; Yamamura, H.I. Life Sc. 1997, 61,
- aryl-aroyl substituted benzofurans as selective CB ! receptor antagonists (e.g. LY -320135) (Felder, CO; Joyce, K.E.; Briley, E.J.; Glass, M.; Mackie, K.P.; Fahey, K.J.; Cullinan, G.J.; Hunden, D.C.; Johnson, D.W.; Chaney, M.O.; Koppel, G.A.; Brownstein, M. J. Pharmacol. Exp. Ther. 1998, 284, 291 ).
- 5-dihydro-1 H-pyrazole compounds which exhibit potent and selective cannabis CB receptor antagonistic activity.
- These compounds have the formula (I) defined below, and have been suggested for use in the treatment of psychiatric disorders such as psychosis, anxiety, depression, attention deficits, memory disorders and appetite disorders, obesity, neurological disorders such as dementia, distonia, Parkinson's disease, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, cerebral ischaemia, as well as for the treatment of pain disorders and other CNS-diseases involving cannabinoid neurotransmission, and in the treatment of gastrointestinal disorders and cardiovascular disorders.
- - R and Ri are the same or different and represent phenyl, thienyl or pyridyl which groups may be substituted with 1 , 2 or 3 substituents Y, which can be the same or different, from the group C 1-3 -alkyl or alkoxy, hydroxy, halogen, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, nitro, amino, mono- or dialkyl (C 1-2 )-amino, mono- or dialkyl (C ⁇ -2 )-amido, (d -3 )-alkyl sulfonyl, dimethylsulfamido, C ⁇ -3 -alkoxycarbonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl, or R and/or R represent naphtyl, - R 2 represents hydrogen, hydroxy, d- 3 -alkoxy
- R 4 and R 5 independently of each other represent hydrogen or C 1 - 8 branched or unbranched alkyl or C 3-8 cycloalkyl or R 4 represents acetamido or dimethylamino or 2,2,2-trifluoroethyl or phenyl or pyridyl with the proviso that R 5 represents hydrogen - R 6 represents hydrogen or C 1-3 unbranched alkyl
- - Bb represents sulfonyl or carbonyl
- R 3 represents benzyl, phenyl, thienyl or pyridyl which may be substituted with 1 , 2 or 3 substituents Y, which can be the same or different, or R 3 represents d -8 branched or unbranched alkyl or C 3-8 cycloalkyl, or R 3 represents naphtyl
- the outstanding unique pharmacological profile of compounds of formula (I) includes particularly high safety and tolerability which make the compounds particularly suitable in patient groups with enhanced need of safety and tolerability, in particular such as juvenile patients and/or patients subject to long term treatment, e.g. in drug induced obesity.
- the compounds used according to the invention are suitable for use in the paediatric treatment and/or prophylaxis of psychiatric disorders such as psychosis, anxiety, depression, attention deficits, memory disorders and appetite disorders, obesity, neurological disorders such as dementia, distonia, Parkinson's disease, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, cerebral ischaemia, as well as for the treatment of pain disorders and other CNS-diseases involving cannabinoid neurotransmission, and in the treatment of gastrointestinal disorders and cardiovascular disorders, in young patients .
- psychiatric disorders such as psychosis, anxiety, depression, attention deficits, memory disorders and appetite disorders, obesity, neurological disorders such as dementia, distonia, Parkinson's disease, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, cerebral ischaemia, as well as for the treatment of pain disorders and other CNS-diseases involving cannabinoid neurotransmission, and in the treatment of gastrointestinal disorders and cardiovascular disorders, in
- the affinity of the compounds of formula (I) for cannabinoid CBi receptors is described in the WO 01/70700, e.g. it was determined using membrane preparations of Chinese hamster ovary (CHO) cells in which the human cannabis CBi receptor is stably transfected in conjunction with [3H]CP-55,940 as radioligand. After incubation of a freshly prepared cell membrane preparation with the [3H]-ligand, with or without addition of compounds of the invention, separation of bound and free ligand was performed by filtration over glassfiber filters. Radioactivity on the filter was measured by liquid scintillation counting.
- the cannabinoid CBi antagonistic activity of compounds of formula (I) is also described in the WO 01/70700, and was determined by functional studies using CHO cells in which human cannabinoid CB receptors are stably expressed.
- Adenylyl cyclase was stimulated using forskolin and measured by quantifying the amount of accumulated cyclic AMP.
- Concomitant activation of CB ! receptors by CBi receptor agonists e.g. CP -55,940 or (R)-WIN-55,212-2
- CBi receptor agonists e.g. CP -55,940 or (R)-WIN-55,212-2
- This CBi receptor-mediated response can be antagonized by CBi receptor antagonists such as the compounds used in the present invention.
- At least one centre of chirality is present (at the C 4 position of the 4,5-dihydro-1 H- pyrazole moiety) in the compounds of the formula (I).
- the invention relates both to the novel use of racemates, mixtures of diastereomers and the individual stereoisomers of the compounds having formula (I).
- the invention also relates both to the novel use of the E isomer, Z isomer and E/Z mixtures of compounds having formula (I) wherein Aa has the meaning (i) or (ii) as described herein above.
- compound having formula (I) are used, wherein R is the group 4-chlorophenyl, Ri is phenyl, R 2 is hydrogen, Aa is the group (i) wherein R 4 is hydrogen and R 5 is methyl, Bb is sulfonyl, and R 3 represents 4-chlorophenyl, and salts thereof.
- the compound having formula (I) used according to the invention may be a levorotatory enantiomer.
- the compounds used in the present the invention can be obtained according to known methods.
- a suitable synthesis for the compounds used according to the present invention is described for compounds of formula (I) in the international patent application WO 01/70700.
- compounds having formula (III) (vide infra), wherein R 2 represents hydrogen can be also obtained according to methods known, for example: a) EP 0021506; b) DE 2529689.
- Example compounds having been prepared according to WO 01/70700 and being investigated include the e.g. the following compounds:
- N-Dimethylamino-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5- dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine N-Methyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-3-(4-chlorophenyl)-4,5- dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine
- the compounds used according to the invention can be brought into forms suitable for paediatric administration, as well as for the administration in treating drug induced obesity by means of usual processes using auxiliary substances and/or liquid or solid carrier materials.
- the invention also pertains to a pharmaceutical composition containing at least one compound of formula (I) as an active component for the treatment and/or prophylaxis of CBi receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as adolescent patients, and at least one auxiliary excipient.
- the compound of formula (I) is preferably present in an amount effectively suited for the treatment and/or prophylaxis of a psychiatric disorder, a gastrointestinal disorder, a cardiovascular disorder, or a combination of said disorders, in a juvenile patient in need of such treating.
- the compound of formula (I) in the pharmaceutical composition is present in an amount effectively suited for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as adolescent patients in need of such treating.
- the invention also includes a method of treatment and/or prophylaxis of
- CBi receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as adolescent patients characterized in that a compound of formula (I) is administered to said patient in need of such treating.
- the method of treatment and/or prophylaxis according to the invention may be further characterized in that the treating is directed to psychiatric disorders such as psychosis, anxiety, depression, attention deficits, memory disorders and appetite disorders, obesity, including drug induced obesity, neurological disorders such as Parkinson's disease, dementia, distonia, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, ischemia, pain and other CNS-diseases involving cannabinoid neurotransmission.
- the method of treatment and/or prophylaxis is directed to the treating of obesity in juvenile patients.
- the method of treatment and/or prophylaxis is directed to the treating of drug induced obesity in juvenile or adolescent patients. This drug induced obesity may be in particular caused by drugs like atypical antipsychotics.
- the method of treatment and/or prophylaxis is directed to the treating of obesity in juvenile patients.
- Cannabinoid antagonists are suitable for the treatment of Childhood Obesity and related Comorbidities as for example Type 2 Diabetes.
- Childhood Obesity and related Comorbidities as for example Type 2 Diabetes.
- the prevalence of overweight in children grew from 5% to 11 % (Sorof and Daniels 2002).
- Obesity in childhood causes a wide range of serious complications, and increases the risk of premature illness and death later in life, raising public-health concerns (Ebbeling,
- Type-2-diabetes was in the past considered a disease of adults and older individuals, not a paediatric condition (Arslanian 2002).
- One of the main risk factor of paediatric type 2 diabetes is obesity.
- Type 2 diabetes in children is part of the insulin resistance syndrome (Rosenbloom 2002) that includes hypertension, dyslipidemia and other atherosclerosis risk factors, and hyperandrogenism seen as premature adrenarche and polycystic ovary syndrome.
- Other outcomes related to childhood obesity include left ventricular hypertrophy, nonalcoholic steatohepatitis, obstructive sleep apnea, orthopedic problems, and severe psychosocial problems.
- CBi antagonists used according to the present invention offer a unique opportunity for the treatment of obesity by interacting with these "driving forces".
- CBi antagonists in childhood are a medical condition that is likely to require long-term management.
- the safety profile of CBi antagonists according to the present invention are suggested to be superior to current standard medications, and these CBi antagonists will be especially suited for the treatment and prevention of childhood obesity and related co-morbidities.
- the method of treatment and/or prophylaxis is directed to the treating of drug induced obesity in juvenile or adolescent patients.
- Drug induced weight gain is also of major concern and subject to high medical need of improved treatments.
- the CBi antagonists according to the present invention are suggested to be superior to current standard medications, and these CB ! antagonists will be especially suited for the treatment and prevention of drug induced obesity in juvenile as well as in adolescent patients.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present invention relates to a novel medical use of 4,5-dihydro-1H-pyrazole compounds which are potent antagonists of the cannabis CB1-receptor. Said compounds are particularly suitable in the manufacture of medicaments for the treatment and/or prophylaxis of CB1 receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as in adolescent patients. The compounds have the general formula (1), wherein the group Bb represents sulfonyl or carbonyl, and the substituents R, R1, R2and R3, and the group Aa are defined as shown in the description.
Description
4 , 5-DIHYDRO- lH-PYRAZOLE DERIVATIVES HAVING CBl-ANTAGONISTIC ACTIVITY
The present invention relates to a group of novel therapeutic and/or prophylactic uses of 4,5-dihydro-1 H-pyrazole derivatives and to pharmaceutical compositions containing one or more of these compounds as an active component for the novel uses. The 4,5-dihydro-1 H-pyrazoles are potent Cannabis-1 (CBi) receptor antagonists with outstanding utility for the novel medical uses provided by the present invention.
Cannabinoids are present in the Indian hemp Cannabis Sativa L. and have been used as medicinal agents for centuries ( echoulam, R.; Feigenbaum, J.J. Prog. Med. Chem. 1987, 24, 159). However, only within the past ten years the research in the cannabinoid area has revealed pivotal information on cannabinoid receptors and their (endogenous) agonists and antagonists. The discovery and the subsequent cloning of two different subtypes of Cannabinoid receptors (CBi and CB2) stimulated the search for novel cannabinoid receptor antagonists (Munro, S.; Thomas, K.L.; Abu-Shaar, M. Nature 1993, 365, 61. Matsuda, L.A.; Bonner, T.I. Cannabinoid Receptors, Pertwee, R.G. Ed. 1995, 1 17, Academic Press, London). In addition, pharmaceutical companies became interested in the development of cannabinoid drugs for the treatment of diseases connected with disorders of the cannabinoid system. The wide distribution of CBT receptors in the brain, in combination with the strictly peripheral localisation of the CB2 receptor, makes the CB! receptor a very interesting molecular target for CNS-directed drug discovery in the areas of both psychiatric and neurological disorders (Consroe, P. Neurobiology of Disease 1998, 5, 534. Pop, E. Curr. Opin. In CPNS
Investigational Drugs 1999, 1, 587. Greenberg, D.A. Drug News Perspect. 1999, 12, 458). Hitherto, three types of distinct CBi receptor antagonists are known. Sanofi disclosed their diarylpyrazole congeners as selective CBi receptor antagonists. A representative example is SR-141716A, which is currently undergoing Phase II clinical development for psychotic disorders (Dutta, A.K.;
Sard, H.; Ryan, W.; Razdan, R.K.; Compton, D.R.; Martin, B.R. Med. Chem. Res. 1994, 5, 54. Lan, R.; Liu, Q.; Fan, P.; Lin, S.; Fernando, S.R.; McCallion, D.; Pertwee, R.; Makriyannis, A. J. Med. Chem. 1999, 42, 769. Nakamura-Palacios, E.M.; Moerschbaecher, J.M.; Barker, L.A. CNS Drug Rev. 1999, 5, 43).
Aminoalkylindoles have been disclosed as CB T receptor antagonists. A representative example is lodopravadoline (AM-630), which was introduced in 1995. AM-630 is a CBi receptor antagonist, but sometimes behaves as a weak partial agonist (Hosohata, K.; Quock, R.M.; Hosohata, Y.; Burkey, T.H.; Makriyannis, A.; Consroe, P.; Roeske, W.R.; Yamamura, H.I. Life Sc. 1997, 61,
PL115). More recently, researchers from Eli Lilly described aryl-aroyl substituted benzofurans as selective CB! receptor antagonists (e.g. LY -320135) (Felder, CO; Joyce, K.E.; Briley, E.J.; Glass, M.; Mackie, K.P.; Fahey, K.J.; Cullinan, G.J.; Hunden, D.C.; Johnson, D.W.; Chaney, M.O.; Koppel, G.A.; Brownstein, M. J. Pharmacol. Exp. Ther. 1998, 284, 291 ). Recently, 3-alkyl-5,5'- diphenylimidazolidinediones were described as cannabinoid receptor ligands, which were indicated to be cannabinoid antagonists (Kanyonyo, M.; Govaerts, S.J.; Hermans, E.; Poupaert, J.H., Lambert, D.M. Biorg. Med.Chem. Lett. 1999, 9, 2233). Interestingly, many CBi receptor antagonists have been reported to behave as inverse agonists in vitro (Landsman, R.S.; Burkey, T.H.; Consroe, P.;
Roeske, W.R.; Yamamura, H.I. Eur. J. Pharmacol. 1997 , 334, R1). Recent reviews provide a nice overview of the current status in the cannabinoid research area (Mechoulam, R.; Hanus, L.; Fride, E. Prog. Med. Chem. 1998, 35, 199. Lambert, D.M. Curr. Med. Chem. 1999, 6, 635. Mechoulam, R.; Fride, E.; Di Marzo, V. Eur. J. Pharmacol. 1998, 359, 1 ).
From the international patent application WO 01/70700 4, 5-dihydro-1 H-pyrazole compounds are known which exhibit potent and selective cannabis CB receptor antagonistic activity. These compounds have the formula (I) defined below, and have been suggested for use in the treatment of psychiatric disorders such as psychosis, anxiety, depression, attention deficits, memory disorders and appetite disorders, obesity, neurological disorders such as dementia, distonia, Parkinson's disease, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, cerebral ischaemia, as well as for the treatment of pain disorders and other CNS-diseases involving cannabinoid neurotransmission, and in the treatment of gastrointestinal disorders and cardiovascular disorders.
It has now surprisingly been found that the 4,5-dihydro-1 H-pyrazole derivatives of the formula (I) which are potent and selective antagonists of the cannabis CBi- receptor, prodrugs thereof, tautomers thereof and salts thereof
wherein - R and Ri are the same or different and represent phenyl, thienyl or pyridyl which groups may be substituted with 1 , 2 or 3 substituents Y, which can be the same or different, from the group C1-3-alkyl or alkoxy, hydroxy, halogen, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, nitro, amino, mono- or dialkyl (C1-2)-amino, mono- or dialkyl (Cι-2)-amido, (d-3)-alkyl sulfonyl, dimethylsulfamido, Cι-3-alkoxycarbonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl, or R and/or R represent naphtyl, - R2 represents hydrogen, hydroxy, d-3-alkoxy, acetyloxy or propionyloxy, - Aa represents one of the groups (i), (ii), (iii), (iv) or (v)
(i) (ϋ) (iϋ) (iv) (v) wherein - R4 and R5 independently of each other represent hydrogen or C1-8 branched or unbranched alkyl or C3-8 cycloalkyl or R4 represents acetamido or dimethylamino or 2,2,2-trifluoroethyl or phenyl or pyridyl with the proviso that R5 represents hydrogen - R6 represents hydrogen or C1-3 unbranched alkyl
- Bb represents sulfonyl or carbonyl, - R3 represents benzyl, phenyl, thienyl or pyridyl which may be substituted with 1 , 2 or 3 substituents Y, which can be the same or different, or R3 represents d-8 branched or unbranched alkyl or C3-8 cycloalkyl, or R3 represents naphtyl
due to their unique pharmacological profile are particularly suited for the use in
the manufacture of a medicaments for the treatment and/or prophylaxis of CB-1 receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis drug induced obesity in juvenile, as well as adolescent, patients. In this regard the compounds of formula (I) are highly valuable in providing medicaments for paediatric use on the one hand, and for the general use in drug induced obesity.
The outstanding unique pharmacological profile of compounds of formula (I) includes particularly high safety and tolerability which make the compounds particularly suitable in patient groups with enhanced need of safety and tolerability, in particular such as juvenile patients and/or patients subject to long term treatment, e.g. in drug induced obesity.
Due to the potent CBT antagonistic activity the compounds used according to the invention are suitable for use in the paediatric treatment and/or prophylaxis of psychiatric disorders such as psychosis, anxiety, depression, attention deficits, memory disorders and appetite disorders, obesity, neurological disorders such as dementia, distonia, Parkinson's disease, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, cerebral ischaemia, as well as for the treatment of pain disorders and other CNS-diseases involving cannabinoid neurotransmission, and in the treatment of gastrointestinal disorders and cardiovascular disorders, in young patients .
The affinity of the compounds of formula (I) for cannabinoid CBi receptors is described in the WO 01/70700, e.g. it was determined using membrane preparations of Chinese hamster ovary (CHO) cells in which the human cannabis CBi receptor is stably transfected in conjunction with [3H]CP-55,940 as radioligand. After incubation of a freshly prepared cell membrane preparation with the [3H]-ligand, with or without addition of compounds of the invention, separation of bound and free ligand was performed by filtration over glassfiber filters. Radioactivity on the filter was measured by liquid scintillation counting.
The cannabinoid CBi antagonistic activity of compounds of formula (I) is also described in the WO 01/70700, and was determined by functional studies using CHO cells in which human cannabinoid CB receptors are stably expressed.
Adenylyl cyclase was stimulated using forskolin and measured by quantifying the amount of accumulated cyclic AMP. Concomitant activation of CB! receptors by CBi receptor agonists (e.g. CP -55,940 or (R)-WIN-55,212-2) can attenuate the forskolin-induced accumulation of cAMP in a concentration -dependent manner.
This CBi receptor-mediated response can be antagonized by CBi receptor antagonists such as the compounds used in the present invention.
The whole content of the international patent application WO 01/70700 is incorporated by reference into the present application.
At least one centre of chirality is present (at the C4 position of the 4,5-dihydro-1 H- pyrazole moiety) in the compounds of the formula (I). The invention relates both to the novel use of racemates, mixtures of diastereomers and the individual stereoisomers of the compounds having formula (I). The invention also relates both to the novel use of the E isomer, Z isomer and E/Z mixtures of compounds having formula (I) wherein Aa has the meaning (i) or (ii) as described herein above.
According to one embodiment of the invention compound having formula (I) are used, wherein R is the group 4-chlorophenyl, Ri is phenyl, R2 is hydrogen, Aa is the group (i) wherein R4 is hydrogen and R5 is methyl, Bb is sulfonyl, and R3 represents 4-chlorophenyl, and salts thereof. The compound having formula (I) used according to the invention may be a levorotatory enantiomer.
The compounds used in the present the invention can be obtained according to known methods. A suitable synthesis for the compounds used according to the present invention is described for compounds of formula (I) in the international patent application WO 01/70700. For example compounds having formula (III) (vide infra), wherein R2 represents hydrogen can be also obtained according to methods known, for example: a) EP 0021506; b) DE 2529689.
Example compounds having been prepared according to WO 01/70700 and being investigated include the e.g. the following compounds:
1 ) 3-(4-Chlorophenyl)-4,5-dihydro-4-hydroxy-4-phenyl-1 H-pyrazole 2) 3-(4-Chlorophenyl)-4,5-dihydro-N-((4-fluorophenyl)sulfonyl)-4-phenyl-1 H- pyrazole-1 -carboxamidine 3) 4,5-Dihydro-N-((4-fluorophenyl)sulfonyl)-3-(4-methoxyphenyl)-4-(4- methoxy-phenyl)-1 H-pyrazole-1 -carboxamidine 4) 4,5-Dihydro-3-(4-methoxyphenyl)-4-(4-methoxyphenyl)-N-((4-methoxy- phenyl)sulfonyl)-1 H-pyrazole-1 -carboxamidine 5) 3-(4-Chlorophenyl)-4,5-dihydro-4-phenyl-N-((2,4,6- trimethylphenyl)sulfonyl)-1 H-pyrazole-1 -carboxamidine
6) 3-(4-Chlorophenyl)-4,5-dihydro-N-((4-fluorophenyl)sulfonyl)-4-hydroxy-4- phenyl-1 H-pyrazole-1 -carboxamidine
7) 3-(4-Chlorophenyl)-4,5-dihydro-N-(1 -naphtoyl)-4-phenyl-1 H-pyrazole-1 - carboxamidine 8) 3-(4-Chlorophenyl)-4,5-dihydro-4-phenyl-N-(2-pyridoyl)-1 H-pyrazole-1 - carboxamidine 9) N ,N1-Dimethyl-N2-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5- dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine 10) N-Methyl-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4- (3-pyridyl)-1 H-pyrazole-1 -carboxamidine
11 ) N-Methyl-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4- (4-pyridyl)-1 H-pyrazole-1 -carboxamidine 12) N1,N1-Dimethyl-N2-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5- dihydro-4-hydroxy-4-phenyl-1 H-pyrazole-1 -carboxamidine 13) N-Ethyl-N-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4- hydroxy-4-phenyl-1 H-pyrazole-1 -carboxamidine
14) N-Methyl-N'-(3-(trifluoromethyl)benzoyl)-3-(4-chlorophenyl)-4,5-dihydro-4- phenyl-1 H-pyrazole-1 -carboxamidine 15) N-Methyl-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4- phenyl-1 H-pyrazole-1 -carboxamidine 16) N-Methyl-N'-((3-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4- phenyl -1 H-pyrazole-1 -carboxamidine 17) N-Methyl-N'-((4-chlorophenyl)sulfonyl)-3-(5-chloro-2-thienyl)-4,5-dihydro-4- phenyl-1 H-pyrazole-1 -carboxamidine
18) N-Propyl-N'-((4-fluorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4- phenyl-1 H-pyrazole-1 -carboxamidine 19) N-(2-Propyl)-N'-((4-fluorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro- 4-phenyl-1 H-pyrazole-1 -carboxamidine 20) N-Methyl-N'-((2-propyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4-phenyl- 1 H-pyrazole-1 -carboxamidine 21 ) N-(2-Propyl)-N'-((4-chlorophenyl)sulfonyl)-3-(4-pyridyl)-4,5-dihydro-4- phenyl-1 H-pyrazole-1 -carboxamidine 22) N1-Ethyl-N1-methyl-N2-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5- dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine
23) N1-Ethyl-N1-methyl-N2-((4-fluorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5- dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine 24) N1,N1-Dimethyl-N2-((4-(trifluoromethyl)phenyl)sulfonyl)-3-(4-chlorophenyl)- 4,5-dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine
N1,N1-Dimethyl-N2-((3-methylphenyl)sulfonyl)-3-(4-chlorophenyl)-4,5- dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine N1,N1-Dimethyl-N2-((3-methoxyphenyl)sulfonyl)-3-(4-chlorophenyl)-4,5- dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine N-Ethyl-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4- phenyl-1 H-pyrazole-1 -carboxamidine
N-Dimethylamino-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5- dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine N-Methyl-N'-((4-(trifluoromethyl)phenyl)sulfonyl)-3-(4-chlorophenyl)-4,5- dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine N1,N1-Dimethyl-N2-((2-methylphenyl)sulfonyl)-3-(4-chlorophenyl)-4,5- dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine
N-Methyl-N'-((2,4-difluorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro- 4-phenyl-1 H-pyrazole-1 -carboxamidine
N-Acetamido-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro- 4-phenyl-1 H-pyrazole-1 -carboxamidine
N-(2,2,2-Trifluoroethyl)-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)- 4,5-dihydro-4-phenyl-1 H-pyrazole-1 -carboxamidine N-(2-Pyridyl)-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro- 4-phenyl -1 H-pyrazole-1 -carboxamidine
N-(4-Pyridyl)-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro- 4-phenyl -1 H-pyrazole-1 -carboxamidine
N-Phenyl-N'-((4-chlorophenyl)sulfonyl)-3-(4-chlorophenyl)-4,5-dihydro-4- phenyl -1 H-pyrazole-1 -carboxamidine
3-(4-Chlorophenyl)-1-[3-((4-chlorophenyl)sulfonyl)butanoyl]-4,5-dihydro-4- phenyl-1 H-pyrazole
3-(4-Chlorophenyl)-1-[3-(phenylsulfonyl)propanoyl]-4,5-dihydro-4-phenyl- 1 H-pyrazole
3-(4-Chlorophenyl)-1-[3-((4-chlorophenyl)sulfonyl)propanoyl]-4,5-dihydro- 4-phenyl-1 H-pyrazole
3-(4-Chlorophenyl)-4,5-dihydro-4-phenyl-1-[2-((3-(trifluoromethyl)phenyl)- sulfonyl)ethyl]-1 H-pyrazole
3-(4-Chlorophenyl)-1-[2-(benzylsulfonyl)ethyl]-4,5-dihydro-4-phenyl-1 H- pyrazole
3-(4-Chlorophenyl)-1-[2-((4-chlorophenyl)sulfonyl)ethyl]-4,5-dihydro-4- phenyl-1 H-pyrazole
3-(4-Chlorophenyl)-1-[2-((4-chlorophenyl)sulfonyl)ethyl]-4,5-dihydro-4- hydroxy-4-phenyl-1 H-pyrazole
44) N-[2-(3-(4-Chlorophenyl)-4,5-dihydro-4-phenyl-1 H-pyrazol-1 -yl)ethyl]-3- (trifluoromethyl)benzenesulfonamide
The compounds used according to the invention can be brought into forms suitable for paediatric administration, as well as for the administration in treating drug induced obesity by means of usual processes using auxiliary substances and/or liquid or solid carrier materials.
Hence, in a further aspect the invention also pertains to a pharmaceutical composition containing at least one compound of formula (I) as an active component for the treatment and/or prophylaxis of CBi receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as adolescent patients, and at least one auxiliary excipient. In such a pharmaceutical composition the compound of formula (I) is preferably present in an amount effectively suited for the treatment and/or prophylaxis of a psychiatric disorder, a gastrointestinal disorder, a cardiovascular disorder, or a combination of said disorders, in a juvenile patient in need of such treating.
In a further embodiment of the invention in the pharmaceutical composition the compound of formula (I) is present in an amount effectively suited for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as adolescent patients in need of such treating.
Finally the invention also includes a method of treatment and/or prophylaxis of
CBi receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as adolescent patients, characterized in that a compound of formula (I) is administered to said patient in need of such treating. The method of treatment and/or prophylaxis according to the invention may be further characterized in that the treating is directed to psychiatric disorders such as psychosis, anxiety, depression, attention deficits, memory disorders and appetite disorders, obesity, including drug induced obesity, neurological disorders such as Parkinson's disease, dementia, distonia, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, ischemia, pain and other CNS-diseases involving cannabinoid neurotransmission.
Preferably, in one embodiment of the invention the method of treatment and/or prophylaxis is directed to the treating of obesity in juvenile patients. In another preferred embodiment of the invention the method of treatment and/or prophylaxis is directed to the treating of drug induced obesity in juvenile or
adolescent patients. This drug induced obesity may be in particular caused by drugs like atypical antipsychotics.
In one embodiment of the invention the method of treatment and/or prophylaxis is directed to the treating of obesity in juvenile patients. Thus, it is advantageous that Cannabinoid antagonists are suitable for the treatment of Childhood Obesity and related Comorbidities as for example Type 2 Diabetes. There is a clear medical need for improved therapy as obesity has become an increasingly important medical problem not only in the adult population but increasingly in children and (young and older) adolescents. In national surveys from the 1960s to the 1990s in the United States, the prevalence of overweight in children grew from 5% to 11 % (Sorof and Daniels 2002). In Canada as another example childhood obesity has tripled in the past 20 years (Spurgeon 2002). Obesity in childhood causes a wide range of serious complications, and increases the risk of premature illness and death later in life, raising public-health concerns (Ebbeling,
Pawlak et al. 2002). Over the last decades a tremendous increase of cases of type 2 diabetes was observed, especially also in children. This epidemic trend is clearly reflecting the increasing rates of obesity. Type-2-diabetes was in the past considered a disease of adults and older individuals, not a paediatric condition (Arslanian 2002). One of the main risk factor of paediatric type 2 diabetes is obesity.
Type 2 diabetes in children (as is in adults) is part of the insulin resistance syndrome (Rosenbloom 2002) that includes hypertension, dyslipidemia and other atherosclerosis risk factors, and hyperandrogenism seen as premature adrenarche and polycystic ovary syndrome. Other outcomes related to childhood obesity include left ventricular hypertrophy, nonalcoholic steatohepatitis, obstructive sleep apnea, orthopedic problems, and severe psychosocial problems.
In addition primary hypertension has become increasingly common in children again associated obesity as a major independent risk factor. Obese children are at approximately a 3-fold higher risk for hypertension than non-obese children (Sorof and Daniels 2002). The benefits of weight loss for blood pressure reduction in children have been demonstrated in both observational and interventional studies.
Public concerns are rising because of a rapid development of the childhood obesity epidemic in genetically stable populations. Driving factors are assumed to
be mainly adverse environmental factors for which straightforward recommendations of life style modifications exists. Obesity and it's related co- morbidities are very serious medical conditions and state of the art measures and treatment of obesity and especially childhood obesity remain largely ineffective at the time being (Ebbeling, Pawlak et al. 2002). The management of type 2 diabetes in is also especially difficult in children and the adolescent age group (Silink 2002). Craving for and over consumption of palatable food is one of the important factors of life-style related obesity in humans and especially also in children and adolescents. Treatment of type 2 diabetes and other co-morbid conditions by the degree of metabolic derangement and symptoms: The only data on the use of oral hypoglycemic agents in children with type 2 diabetes has been with metformin (Rosenbloom 2002).
Thus, CBi antagonists used according to the present invention offer a unique opportunity for the treatment of obesity by interacting with these "driving forces".
They are superior to current medical treatments and especially suited for pediatric treatment because of their outstanding safety profile and/or tolerability. Treatment of obesity especially childhood obesity is besides efficacy dictated by safety.
Obesity in childhood is a medical condition that is likely to require long-term management. The safety profile of CBi antagonists according to the present invention are suggested to be superior to current standard medications, and these CBi antagonists will be especially suited for the treatment and prevention of childhood obesity and related co-morbidities.
Literature:
Arslanian, S. (2002). "Type 2 diabetes in children: clinical aspects and risk factors." Horm Res 57 Suppl 1 : 19-28. Ebbeling, C. B., D. B. Pawlak, et al. (2002). "Childhood obesity: public-health crisis, common sense cure." Lancet 360(9331 ): 473-82.
Rosenbloom, A. L. (2002). "Increasing incidence of type 2 diabetes in children and adolescents: treatment considerations." Paediatr Drugs 4(4): 209-21.
Silink, M. (2002). "Childhood diabetes: a global perspective." Horm Res 57 Suppl 1 : 1-5.
Sorof, J. and S. Daniels (2002). "Obesity hypertension in children: a problem of epidemic proportions." Hypertension 40(4): 441 -7.
Spurgeon, D. (2002). "Childhood obesity in Canada has tripled in past 20 years." Bmi 324(7351 ): 1416.
In another embodiment of the invention the method of treatment and/or prophylaxis is directed to the treating of drug induced obesity in juvenile or adolescent patients. Drug induced weight gain is also of major concern and subject to high medical need of improved treatments. Again, in this context the CBi antagonists according to the present invention are suggested to be superior to current standard medications, and these CB! antagonists will be especially suited for the treatment and prevention of drug induced obesity in juvenile as well as in adolescent patients.
Regarding drug induced weight gain, it is reported by Zimmermann, U., T. Kraus, et al. (2003, "Epidemiology, implications and mechanisms underlying drug- induced weight gain in psychiatric patients." J Psychiatr Res 37(3): 193-220) that body weight gain frequently occurs during drug treatment of psychiatric disorders and is often accompanied by increased appetite or food craving. While occurrence and time course of this side effect are difficult to predict, it ultimately results in obesity and the morbidity associated therewith in a substantial part of patients, often causing them to discontinue treatment even if it is effective. Weight gain appears to be most prominent in patients treated with some of the second generation antipsychotic drugs and with some mood stabilizers. Marked weight gain also frequently occurs during treatment with most tricyclic antidepressants.
Very large weight gains are associated with drugs like for example the atypical antipsychotics clozapine and olanzapine. Some atypical antipsychotics, however, tend to cause significant weight gain, which may lead to poor compliance and other adverse health effects (Nasrallah, H. (2003). "A review of the effect of atypical antipsychotics on weight." Psychoneuroendocrinology 28 Suppl 1 : 83- 96.). The mechanisms involved in antipsychotic drug-related weight gain are as yet uncertain, although serotoninergic, histaminic, and adrenergic affinities have been implicated along with other metabolic mechanisms. The atypical antipsychotics vary in their propensity to cause weight change with long-term treatment. Follow-up studies show that the largest weight gains are associated with clozapine and olanzapine, and the smallest with quetiapine and ziprasidone. Risperidone is associated with modest weight changes that are not dose related.
Given the equivalent efficacy of atypical antipsychotics, weight-gain profile is a legitimate factor to consider when constructing an algorithm for treatment due to the serious medical consequences of obesity. In this regard co-administration of CBT antagonist according to the invention is suggested to work beneficially.
Claims
1. Use of a CB1 receptor antagonistic compound of formula (I), prodrugs thereof, tautomers thereof and salts thereof, in the manufacture of medicaments for the treatment and/or prophylaxis of CBi receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as in adolescent patients:
wherein - R and Ri are the same or different and represent phenyl, thienyl or pyridyl which groups may be substituted with 1 , 2 or 3 substituents Y, which can be the same or different, from the group Cι-3-alkyl or alkoxy, hydroxy, halogen, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, nitro, amino, mono- or dialkyl (C1-2)-amino, mono- or dialkyl (C1-2)-amido, (C1-3)-alkyl sulfonyl, dimethylsulfamido, Cι-3-alkoxycarbonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl, or R and/or RT represent naphtyl, - R2 represents hydrogen, hydroxy, C1-3-alkoxy, acetyloxy or propionyloxy, - Aa represents one of the groups (i), (ii), (iii), (iv) or (v)
(i) (ϋ) (iii) (iv) (v) wherein R4 a nd R independently of each other represent hydrogen or C1-8 branched or unbranched alkyl or C3-8 cycloalkyl or R4 represents acetamido or dimethylamino or 2,2,2-trifluoroethyl or phenyl or pyridyl with the proviso that R5 represents hydrogen - R6 represents hydrogen or Cι-3 unbranched alkyl - Bb represents sulfonyl or carbonyl, - R3 represents benzyl, phenyl, thienyl or pyridyl which may be substituted with 1 , 2 or 3 substituents Y, which can be the same or different, or R3 represents C1.8 branched or unbranched alkyl or C3-8 cycloalkyl, or R3 represents naphtyl.
2. Use of the compound having formula (I) according to claim 1 , wherein R is the group 4-chlorophenyl, Ri is phenyl, R2 is hydrogen, Aa is the group (i) wherein R4 is hydrogen and R5 is methyl, Bb is sulfonyl, and R3 represents 4- chlorophenyl, and salts thereof.
3. Use of the compound having formula (I) according to claim 1 , wherein the compound is a levorotatory enantiomer.
4. A pharmaceutical composition containing at least one compound of formula (I) as defined in claim 1 as an active component for the treatment and/or prophylaxis of CBi receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as adolescent patients, and at least one auxiliary excipient.
5. A pharmaceutical composition according to claim 4, wherein the at least one compound of formula (I) is present in an amount effectively suited for the treatment and/or prophylaxis of a psychiatric disorder, a gastrointestinal disorder, a cardiovascular disorder, or a combination of said disorders, in a juvenile patient in need of such treating.
6. A pharmaceutical composition according to claim 4, wherein the at least one compound of formula (I) is present in an amount effectively suited for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as adolescent patients in need of such treating.
7. A method of treatment and/or prophylaxis of CBi receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as adolescent patients, characterized in that a compound of formula (I) as defined in claim 1 is administered to said patient in need of such treating.
8. A method of treatment and/or prophylaxis according to claim 7, characterized in that the treating is directed to psychiatric disorders such as psychosis, anxiety, depression, attention deficits, memory disorders and appetite disorders, obesity, including drug induced obesity, neurological disorders such as Parkinson's disease, dementia, distonia, Alzheimer's disease, epilepsy, Huntington's disease, Tourette's syndrome, ischaemia, pain and other CNS-diseases involving cannabinoid neurotransmission.
9. A method of treatment and/or prophylaxis according to claim 8, characterized in that the treating is directed to obesity in juvenile patients.
10. A method of treatment and/or prophylaxis according to claim 8, characterized in that the treating is directed to drug induced obesity in juvenile or adolescent patients.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04766644A EP1663205A1 (en) | 2003-09-02 | 2004-08-31 | Use of 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03019939 | 2003-09-02 | ||
PCT/EP2004/051961 WO2005020988A1 (en) | 2003-09-02 | 2004-08-31 | Use of 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
EP04766644A EP1663205A1 (en) | 2003-09-02 | 2004-08-31 | Use of 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1663205A1 true EP1663205A1 (en) | 2006-06-07 |
Family
ID=34259159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04766644A Withdrawn EP1663205A1 (en) | 2003-09-02 | 2004-08-31 | Use of 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1663205A1 (en) |
JP (1) | JP2007504200A (en) |
CN (2) | CN1835747A (en) |
AR (1) | AR045533A1 (en) |
AU (1) | AU2004268388A1 (en) |
BR (1) | BRPI0413980A (en) |
CA (1) | CA2537090A1 (en) |
MX (1) | MXPA06002365A (en) |
RU (1) | RU2006110543A (en) |
TW (1) | TW200511990A (en) |
WO (1) | WO2005020988A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1747926A (en) | 2002-12-19 | 2006-03-15 | 麦克公司 | The substituted amide compound |
US7700597B2 (en) | 2004-12-03 | 2010-04-20 | Schering Corporation | Substituted piperazines as CB1 antagonists |
WO2009140210A2 (en) * | 2008-05-12 | 2009-11-19 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Radiotracers for imaging cannabinoid sub-type1 (cb1) receptor |
WO2010079241A1 (en) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Use of antagonists and/or inverse agonists of cb1 receptors for the preparation of drugs that increase motor neuron excitability |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DZ3335A1 (en) * | 2000-03-23 | 2001-09-27 | Solvay Pharm Bv | 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING ANTIAGONIST ACTIVITY OF CB1 |
BR0205602A (en) * | 2001-03-22 | 2003-07-08 | Solvay Pharm Bv | Enantiomer having the 4-position configuration of its pyrazole ring of a compound, pharmaceutical composition, method for preparing pharmaceutical compositions, process for preparing compounds, and methods for treating disorders involving cannabinoid neurotransmission |
CN1555262A (en) * | 2001-09-21 | 2004-12-15 | ������ҩ������˾ | Novel 4,5-dihydro-1H-pyrazole derivatives having CB*-antagonistic activity |
-
2004
- 2004-08-30 AR ARP040103109A patent/AR045533A1/en not_active Application Discontinuation
- 2004-08-30 TW TW093125980A patent/TW200511990A/en unknown
- 2004-08-31 CA CA002537090A patent/CA2537090A1/en not_active Abandoned
- 2004-08-31 JP JP2006525143A patent/JP2007504200A/en active Pending
- 2004-08-31 CN CNA2004800234935A patent/CN1835747A/en active Pending
- 2004-08-31 BR BRPI0413980-1A patent/BRPI0413980A/en not_active IP Right Cessation
- 2004-08-31 EP EP04766644A patent/EP1663205A1/en not_active Withdrawn
- 2004-08-31 WO PCT/EP2004/051961 patent/WO2005020988A1/en active Application Filing
- 2004-08-31 CN CNA2004800248995A patent/CN1845735A/en active Pending
- 2004-08-31 RU RU2006110543/15A patent/RU2006110543A/en not_active Application Discontinuation
- 2004-08-31 AU AU2004268388A patent/AU2004268388A1/en not_active Abandoned
- 2004-08-31 MX MXPA06002365A patent/MXPA06002365A/en not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO2005020988A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU2004268388A1 (en) | 2005-03-10 |
BRPI0413980A (en) | 2006-11-07 |
RU2006110543A (en) | 2007-10-10 |
AR045533A1 (en) | 2005-11-02 |
CN1835747A (en) | 2006-09-20 |
TW200511990A (en) | 2005-04-01 |
MXPA06002365A (en) | 2006-06-20 |
CN1845735A (en) | 2006-10-11 |
CA2537090A1 (en) | 2005-03-10 |
WO2005020988A1 (en) | 2005-03-10 |
JP2007504200A (en) | 2007-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lange et al. | Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists | |
Kumar et al. | Biological activities of pyrazoline derivatives-A recent development | |
TW450808B (en) | Use of central cannabinoid receptor antagonists for the preparation of drugs | |
US20050101585A1 (en) | Use of selective CB1-antagonists in medical treatments | |
ZA200402099B (en) | Novel 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity. | |
US20050124660A1 (en) | Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds | |
US20130237572A1 (en) | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents | |
US20050080125A1 (en) | Novel medical uses of 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | |
AU2008252075A1 (en) | Hydrazonopyrazole derivatives and their use as therapeutics | |
TW200812576A (en) | Novel use of CBx cannabinoid receptor modulators as potassium channel modulators | |
WO2012162025A1 (en) | Methods of selecting cancer patients for treatment with n,n'-diarylurea compounds and n,n'-diarylthiourea compounds | |
EP1663205A1 (en) | Use of 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity | |
CA2650566A1 (en) | Pharmaceutical compositions comprising cbx cannabinoid receptor modulators and potassium channel modulators | |
WO2005039550A2 (en) | Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds | |
EP1680106B1 (en) | Combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity and lipase inhibitors | |
US20050143441A1 (en) | Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | |
JP2005029573A (en) | Tumor metastasis inhibitor | |
EP1793821A2 (en) | Pyrazolone compounds for treating cerebrovascular disorders | |
CA2543197A1 (en) | Combination treatment of obesity involving selective cb1-antagonists and lipase inhibitors | |
JP2006096664A (en) | Hepatic fibrosis inhibitor | |
CA2518579A1 (en) | Method for appetite suppression | |
JP2008037753A (en) | Therapeutic and/or preventive agent for pruritus | |
WO2007009692A1 (en) | Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes | |
JP2006298786A (en) | Agent for suppressing formation of 2-methyl-1,3,4-thiadiazole-1-thiol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060403 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20070802 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20110301 |